Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
Genetic Abnormality Predicts Treatment Benefit for Patients with Rare Brain Tumor
(Posted: 02/09/2012) - The addition of chemotherapy to radiation therapy doubled the median survival time for certain patients with an aggressive form of oligodendroglioma, a rare brain tumor.
Exemestane Following Tamoxifen Reduces Breast Cancer Recurrences and Prolongs Survival
(Posted: 02/01/2012) - Long-term follow-up data from a large international phase III trial shows that postmenopausal women with early-stage hormone receptor-positive breast cancer who received 2 to 3 years of tamoxifen and then switched to the drug exemestane (Aromasin®) for a total of 5 years of adjuvant hormone therapy experienced a delay in disease recurrence and a survival advantage, compared with women who took tamoxifen for 5 years.
Late Effects May Not Warrant Using Radiation to Treat Early-Stage Hodgkin Lymphoma
(Posted: 12/22/2011) - Patients with early-stage Hodgkin lymphoma who were treated with multidrug chemotherapy alone were more likely to be alive 12 years later than patients who received treatment that included radiation therapy, according to findings from a phase III clinical trial.
Combination Therapy Shows Promise for Treating Advanced Breast Cancer
(Posted: 12/21/2011) - Adding the drug everolimus (Afinitor®) to exemestane helped postmenopausal women whose advanced breast cancer had stopped responding to hormonal therapy live about 4 months longer without the disease progressing than women who received exemestane alone.
Two Drugs that Hit One Target Show Efficacy against Metastastic Breast Cancer
(Posted: 12/21/2011) - Combining two drugs that target the HER2 protein, trastuzumab (Herceptin®) and the investigational agent pertuzumab, with chemotherapy may be a new treatment option for women with HER2-positive metastatic breast cancer, according to results from a large clinical trial.
(Posted: 02/09/2012) - The addition of chemotherapy to radiation therapy doubled the median survival time for certain patients with an aggressive form of oligodendroglioma, a rare brain tumor.
Exemestane Following Tamoxifen Reduces Breast Cancer Recurrences and Prolongs Survival
(Posted: 02/01/2012) - Long-term follow-up data from a large international phase III trial shows that postmenopausal women with early-stage hormone receptor-positive breast cancer who received 2 to 3 years of tamoxifen and then switched to the drug exemestane (Aromasin®) for a total of 5 years of adjuvant hormone therapy experienced a delay in disease recurrence and a survival advantage, compared with women who took tamoxifen for 5 years.
Late Effects May Not Warrant Using Radiation to Treat Early-Stage Hodgkin Lymphoma
(Posted: 12/22/2011) - Patients with early-stage Hodgkin lymphoma who were treated with multidrug chemotherapy alone were more likely to be alive 12 years later than patients who received treatment that included radiation therapy, according to findings from a phase III clinical trial.
Combination Therapy Shows Promise for Treating Advanced Breast Cancer
(Posted: 12/21/2011) - Adding the drug everolimus (Afinitor®) to exemestane helped postmenopausal women whose advanced breast cancer had stopped responding to hormonal therapy live about 4 months longer without the disease progressing than women who received exemestane alone.
Two Drugs that Hit One Target Show Efficacy against Metastastic Breast Cancer
(Posted: 12/21/2011) - Combining two drugs that target the HER2 protein, trastuzumab (Herceptin®) and the investigational agent pertuzumab, with chemotherapy may be a new treatment option for women with HER2-positive metastatic breast cancer, according to results from a large clinical trial.
